NICE recommends the PARP inhibitor niraparib for ovarian cancer treatment via the NHS

A PARP inhibitor, termed Zejula® (niraparib), has been endorsed for routine use in the NHS by the National Institute for Health Care and Excellence (NICE, UK) to treat some forms of ovarian, peritoneal or fallopian tube cancer. Niraparib is a capsule to be taken once daily. It will be available for those with various forms of fallopian tube, ovarian or peritoneal cancer who meet specific criteria. Niraparib is recommended for individuals whose cancer has relapsed, contains a BRCA mutation and who have received two courses of platinum-based chemotherapy. Niraparib can also be utilized for patients with these types of cancer...